Condor Software, which created the first financial cloud for biopharma research and development (R&D), today announced significant enhancements to its Forecast and Scenario Planning Suite. Designed specifically for biopharma R&D finance teams, the enhanced suite now includes advanced benchmarking capabilities to complement existing automation, real-time insights, and predictive analytics. These upgrades enable finance leaders to more precisely forecast R&D costs, rapidly model financial scenarios, and accelerate strategic decision-making.

This enhanced Forecast and Scenario Planning Suite represents the ongoing expansion of the Condor Cloud, reinforcing Condor's established position as the trusted, industry-leading platform delivering unmatched financial clarity, efficiency, and informed strategic insights across the spectrum of biopharma R&D. The Forecast and Scenario Planning Suite is one of three product suites that comprise the Condor Cloud, one of which is slated for release later this year.

"Condor is revolutionizing the way biopharma companies manage their clinical research and development finances," said Jennifer Kyle, the company's CEO and Founder. "Our software powers intelligent workflows, aggregates critical clinical and financial data, and drives smarter, faster decisions. This new enhancement enables us to broaden our coverage and insights needed for financial planning, eliminating guesswork with outdated, error-prone processes in an industry where time and innovation are critical. The Condor Cloud was built by biopharma finance veterans to address head-on clinical finance challenges. We are proud to see the differences our technology has made possible so far and look forward to continuing the transformation through additional product suite releases." 

First introduced in 2020, the Condor Cloud emerged from Kyle's vision of empowering biopharma finance teams with the broadest, clearest, and deepest insights. As a CPA and financial consultant to biopharma companies at a time when R&D spending exceeded $300 billion annually, Kyle experienced first-hand the reliance on inefficient manual spreadsheets, disconnected systems, complex accrual processes, and unreliable budgeting and forecasting. To address these challenges, she collaborated with leading biopharma companies and Big 4 accounting firms to design and launch a comprehensive financial cloud solution for R&D. Condor Cloud brings end-to-end automation, eliminating manual accrual management, vendor reconciliation headaches, and cumbersome contract adjustments while seamlessly integrating clinical and financial data. With the new benchmarking enhancements to the Forecast and Scenario Planning Suite, the Condor Cloud provides biopharma teams with unprecedented forecasting precision with transparency, accelerated financial planning cycles, and strategic scenario planning capabilities to confidently navigate financial complexities and optimize clinical portfolios.

Condor Cloud has rapidly gained adoption, currently serving more than 150 active users across biopharma teams. Since the launch of Condor Cloud, users have documented significant outcomes, including:

• More than 75% improvements in efficiency across accounting and vendor management workflows
• More than 90% increases in forecast accuracy by leveraging Condor's proprietary data-driven insights and clinical financial algorithms
• Financial savings of up to 10% of clinical trial budgets achieved by improving vendor oversight and expense predictability
• Accelerated financial closing cycles and simplified financial reconciliation

In addition, one biopharma company successfully scaled a clinical development program from two to 15 trials without additional headcount, saving more than $5 million in program costs. Users attribute these outcomes to Condor's automation, data intelligence, and seamless integration with clinical trial management, ERP, and financial planning systems.